Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2012

OncoEthix Gains Rights to Mitsubishi Tanabe’s Anticancer Bromodomain Inhibitor

  • Swiss cancer drug developer OncoEthix negotiated a license to Mitsubishi Tanabe Pharma’s bromodomain inhibitor OTX015. The synthetic small molecule targets BET bromodomains 2, 3, and 4 and has completed a Phase I study. OncoEthix says it plans to start additional studies during 2012.

    Recent research indicates that inhibiting BRD2/3/4/ downregulates MYC transcription, which leads to downregulation of MYC-dependent target genes. “The studies that we performed have confirmed that OTX015 is active across a wide range of hematological malignancies,” states Esteban Cvitkovic, M.D., CSL.

    OTX015 is the third anticancer compound licensed in by OncoEthix since its foundation in 2007. Lead compound OTX008 is a synthetic small molecule galectin-1 inhibitor, which started in Phase I trials in patients with advanced solid tumors earlier this year. The firm’s discovery-stage compound OTX009 is a synthetic small molecule that is active in cancer cells with an epithelial phenotype that are sensitive to standard chemotherapy drugs and signal transduction modulators as well as cancer cells with mesenchymal phenotype that are highly resistant to such agents.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »